Penetration and participation rates of women at risk of gestational diabetes in mHealth coaching diabetes prevention and weight management intervention: The Bump2Baby and Me study

O'Reilly SL¹, Geraghty AA¹, McAuliffe F¹, Burden C², Campoy C³, Teede H⁴, Laws R⁵, Campbell K⁵, V Versace⁵, Harrison C⁴, Andresen J⁶, Norman J², Terkildsen-Maindal H⁷, Skinner TC⁸, on behalf of the IMPACT DIABETES B2B Collaboration Group

¹University College Dublin and National Maternity Hospital, Ireland, ² University of Bristol, ³ University of Granada and affiliated hospitals, Spain, ⁴ Monash University and Monash Health, Australia, ⁵ Deakin University, Australia, ⁶ Liva Healthcare, Denmark and UK, ⁷Aarhus University, Denmark, ⁸University of Copenhagen, Denmark and La Trobe University, Australia

Background

Gestational diabetes (GDM) affects up to 18% of pregnancies and increase both a woman's and child's risk of developing non-communicable diseases such as type 2 diabetes. Lifestyle interventions during pregnancy can limit excess gestational weight gain and reduce non-communicable disease risk such as diabetes and obesity¹. However, existing interventions have not moved beyond the research phase to consider routine health implementation. Study reach and



Table 1: Penetration and Participation Data for Ireland, UK, Spain and Australia

Site	Screened (n)	Eligible (n)	Penetration rate (%)	Invited to trial (n)	Enrolled in trial (n)	Participation Rate (%)
Dublin	653	373	57.12	354	193	54.52
Bristol	1336	519	38.85	360	201	55.83
Granada	1006	319	31.71	203	188	92.61
Melbourne	1398	463	33.12	463	127	27.43
Total	4393	1674	38.11	1380	709	51.38

participation rates are rarely recorded.²

IMPACT DIABETES B2B aims to demonstrate the real-world implementation of an evidence-based system of care for the prevention of diabetes, overweight and obesity when delivered 'at scale' in antenatal settings. **Bump2Baby and Me** is the **multicentre randomised controlled trial** (RCT) central to the project that aims to investigate a mHealth coaching program for women who are at high risk of developing GDM. The trial registration is ACTRN12620001240932.

Methodology

Study Design


Women attending maternity services in Dublin, Granada, Melbourne and Bristol for their first antenatal appointment were screened for eligibility. Eligible women received further trial information and were invited to participate (Figure 1). Participants are enrolled at approx. 12 weeks' gestation and randomised on a 1:1 basis into the **intervention** or **control** arm.

• Intervention: mHealth coaching delivered via a smartphone application, using a mixture of synchronous and asynchronous video and text messaging to allow

Women scoring **3+** were eligible for the study and received further information before being invited to participate.

- **Penetration rate:** Calculated as the number of women eligible to take part within the general maternity service population.
- **Participation rate:** Calculated as the number of eligible women who agreed to take part in the study.

8th February 2021 to 31st November 2021: **4,393** women were screened for study eligibility. 1,674 women met the criteria for increased GDM risk and study eligibility. Penetration rate was 38% (Figure 2). 1,380 women were invited to take part in the study with 709 signing up. Participation rate was 51% (Figure 3).




for personalised support and goal setting with a personal health coach from early pregnancy to 12 months postpartum.

• Control: Standard information provision and usual antenatal and postnatal care.

Participants

Women attending for their first antenatal appointment were screened for study eligibility using the validated Monash GDM screening tool³.



Almost 40% the women attending routine antenatal services across 4 busy maternity services in Spain, Ireland, UK and Australia have risk factors for developing GDM. Over half of the population are **interested** in participating in research.

Acknowledgements: Thanks to the mothers and their babies who are participating in our



Figure 1: Bump2Baby and Me Study Recruitment Process

research.

Bump2BabyandMe

References: 1. Lindström et al. Lancet. 2006;368(9548):1673–9. 2. Dasgupta et al. Diabetes Res Clin Pract. 2018;145:200–13. 3. Teede et al., ANZJOG 2011;51(6):499–504





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No.847984.



The project acknowledges funding from the National Health and Medical Research Council, grant #GNT1194234.



Australian Government

National Health and Medical Research Council

www.bump2babyandme.org

